Table 7.
Medication | Number of arms* | Estimated odds ratio (95% CI) |
---|---|---|
Nicotine patch (reference group) | 32 | 1.0 |
Monotherapies | ||
Varenicline (2 mg/day) | 5 | 1.6 (1.3, 2.0) |
Nicotine nasal spray | 4 | 1.2 (0.9, 1.6) |
High dose nicotine patch (>25 mg; standard or long-term) | 4 | 1.2 (0.9, 1.6) |
Long-term nicotine gum (>14 weeks) | 6 | 1.2 (0.8, 1.7) |
Varenicline (1 mg/day) | 3 | 1.1 (0.8, 1.6) |
Nicotine Inhaler | 6 | 1.1 (0.8, 1.5) |
Clonidine | 3 | 1.1 (0.6, 2.0) |
bupropion SR | 26 | 1.0 (0.9, 1.2) |
Long-term nicotine patch (>14 weeks) | 10 | 1.0 (0.9, 1.2) |
Nortriptyline | 5 | 0.9 (0.6, 1.4) |
Nicotine Gum | 15 | 0.8 (0.6, 1.0) |
Combination therapies | ||
Patch (long-term; >14 weeks) + NRT (gum or spray) | 3 | 1.9 (1.3, 2.7) |
Patch + bupropion SR | 3 | 1.3 (1.0, 1.8) |
Patch + nortriptyline | 2 | 0.9 (0.6, 1.4) |
Patch + inhaler | 2 | 1.1 (0.7, 1.9) |
Second-generation antidepressants & Patch | 3 | 1.0 (0.6, 1.7) |
Medications not shown to be effective | ||
Selective serotonin reuptake inhibitors (SSRIs) | 3 | 0.5 (0.4, 0.7) |
Naltrexone | 2 | 0.3 (0.1, 0.6) |
The term “arms” refers to the separate treatment or control groups comprised by the analyzed studies.